关于Aflibercept生物仿制药的临床试验:一篇综述
HyunWoo Lee1, Ashish Sharma2, Se Joon Woo1
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
概括
阿弗利塞普特生物类似药的开发为治疗视网膜疾病提供了具有成本效益的替代方案. 本综述比较了aflibercept生物类似药的III期临床试验设计,以确保有效实施.
科学领域:
- 眼科医生 眼科 眼科
- 药物经济学 药物经济学
- 生物技术是生物技术.
背景情况:
- 抗血管内皮生长因子 (VEGF) 生物药物已经改变了视网膜疾病的管理.
- 专利过期导致了对拉尼比祖马布和阿弗利伯塞普特的生物类似药的开发.
- 在2024年市场独家权到期后,Aflibercept生物类似药正在出现.
研究的目的:
- 为aflibercept生物类似药提供第三期临床试验设计的全面比较.
- 帮助理解生物类似研究设计,减轻负面看法.
- 促进aflibercept生物类似药的积极实施.
主要方法:
- 对aflibercept生物类似药发表的第三期临床试验设计的审查和比较.
- 对研究方法,终点和患者群体的分析.
- 包括最近发表的试验结果.
主要成果:
- 在aflibercept生物类似药的第三期临床试验中使用的方法的详细比较.
- 在试验设计中识别共同点和差异.
- 综合了最近发表的aflibercept生物类似试验的研究结果.
结论:
- 了解生物类似试验设计对于其接受和实施至关重要.
- 阿弗利塞普特生物仿制药提供了临床上同等且具有成本效益的替代品.
- 这一审查有助于就aflibercept生物类似药的采用做出明智的决策.
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
9.3K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.3K
Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Open Angle Glaucoma: Treatment
597
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
597


